These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 19182205)
1. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Knop S; Gerecke C; Liebisch P; Topp MS; Platzbecker U; Sezer O; Vollmuth C; Falk K; Glasmacher A; Maeder U; Einsele H; Bargou RC Blood; 2009 Apr; 113(18):4137-43. PubMed ID: 19182205 [TBL] [Abstract][Full Text] [Related]
2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
3. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748 [TBL] [Abstract][Full Text] [Related]
4. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206 [TBL] [Abstract][Full Text] [Related]
6. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667 [TBL] [Abstract][Full Text] [Related]
7. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423 [TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079 [TBL] [Abstract][Full Text] [Related]
10. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC; Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Baz RC; Shain KH; Hussein MA; Lee JH; Sullivan DM; Oliver EF; Nardelli LA; Nodzon LA; Zhao X; Ochoa-Bayona JL; Nishihori T; Dalton WS; Alsina M Am J Hematol; 2014 Jan; 89(1):62-7. PubMed ID: 24030918 [TBL] [Abstract][Full Text] [Related]
13. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344 [TBL] [Abstract][Full Text] [Related]
14. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135 [TBL] [Abstract][Full Text] [Related]
15. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761 [TBL] [Abstract][Full Text] [Related]
16. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001 [TBL] [Abstract][Full Text] [Related]
17. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Kumar SK; Flinn I; Noga SJ; Hari P; Rifkin R; Callander N; Bhandari M; Wolf JL; Gasparetto C; Krishnan A; Grosman D; Glass J; Sahovic EA; Shi H; Webb IJ; Richardson PG; Rajkumar SV Leukemia; 2010 Jul; 24(7):1350-6. PubMed ID: 20508619 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Baz R; Walker E; Karam MA; Choueiri TK; Jawde RA; Bruening K; Reed J; Faiman B; Ellis Y; Brand C; Srkalovic G; Andresen S; Knight R; Zeldis J; Hussein MA Ann Oncol; 2006 Dec; 17(12):1766-71. PubMed ID: 16980599 [TBL] [Abstract][Full Text] [Related]
20. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]